Traditionally, peripherally inserted central catheters (PICCs) need to have their locations verified with a CT scan. According to the FDA, that is no longer necessary when using the Celerity tip location system from AngioDynamics.
The system works by utilizing the patient's cardiac electrical activity to provide real time catheter tip location. Testing has suggested that it provides accuracy on par with similar devices currently marketed, at or above 97% as compared to chest X-ray.
For AngioDynamics, this FDA approval may unleash greater consumer interest in their BioFlo line of catheters, which can work in conjunction with the Celerity system and reduces the incidence of life-threatening blood clots.
One of the more common procedures warranting PICCs is a clogged artery repair. Being able to perform and validate that procedure at the bedside instead of the CT scanner could mean big news for hospitals and patients alike.
"The cost savings associated with using the Celerity system to aid in PICC placements has created a strong demand from our clients," said Chuck Greiner, Senior Vice President of AngioDynamics' Vascular Access Business, in a statement.
"This expanded indication promises to reduce supply and labor cost for our customers, as well as optimize patient care by decreasing delays in treatment. Coupled with its ease of use with our thromboresistant BioFlo PICCs, the Celerity system will improve patient outcomes while reducing health care costs to many more hospitals and patients across the U.S.," said Greiner.
